CA2104686A1 - Delayed Release Oral Dosage Forms for Treatment of Intestinal Disorders - Google Patents
Delayed Release Oral Dosage Forms for Treatment of Intestinal DisordersInfo
- Publication number
- CA2104686A1 CA2104686A1 CA2104686A CA2104686A CA2104686A1 CA 2104686 A1 CA2104686 A1 CA 2104686A1 CA 2104686 A CA2104686 A CA 2104686A CA 2104686 A CA2104686 A CA 2104686A CA 2104686 A1 CA2104686 A1 CA 2104686A1
- Authority
- CA
- Canada
- Prior art keywords
- granules
- drug
- treatment
- coated
- dosage forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
An orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprises a plurality of enteric coated granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine. The granules are preferably coated with a coating which remains intact until the coated granules reach at least the ileum and thereafter provide a sustained release of the drug in the colon. Suitable coating materials are selected from the Eudragit range of (meth)acrylate and (meth)acrylic acid polymers. The invention has particular application to topically active drugs such as topically active steroids, bismuth salts and complexes, and especially, 5-amino-salicylic acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9103795.2 | 1991-02-22 | ||
GB9103795A GB2253346A (en) | 1991-02-22 | 1991-02-22 | Delayed release oral dosage forms for treatment of intestinal disorders |
PCT/GB1992/000318 WO1992014452A1 (en) | 1991-02-22 | 1992-02-21 | Delayed release oral dosage forms for treatment of intestinal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2104686A1 true CA2104686A1 (en) | 1992-08-23 |
CA2104686C CA2104686C (en) | 2000-05-02 |
Family
ID=10690451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002104686A Expired - Lifetime CA2104686C (en) | 1991-02-22 | 1992-02-21 | Delayed release oral dosage forms for treatment of intestinal disorders |
Country Status (23)
Country | Link |
---|---|
US (1) | US5401512A (en) |
EP (1) | EP0572486B1 (en) |
JP (1) | JP2958116B2 (en) |
KR (1) | KR100220322B1 (en) |
AT (1) | ATE129893T1 (en) |
AU (1) | AU652032B2 (en) |
CA (1) | CA2104686C (en) |
CZ (1) | CZ281792B6 (en) |
DE (1) | DE69205971T2 (en) |
DK (1) | DK0572486T3 (en) |
ES (1) | ES2079183T3 (en) |
FI (1) | FI105255B (en) |
GB (1) | GB2253346A (en) |
GE (1) | GEP19971086B (en) |
GR (1) | GR3018455T3 (en) |
HU (1) | HU219449B (en) |
IE (1) | IE74225B1 (en) |
IL (1) | IL101036A (en) |
IN (1) | IN179089B (en) |
NO (1) | NO307405B1 (en) |
NZ (1) | NZ241687A (en) |
WO (1) | WO1992014452A1 (en) |
YU (1) | YU17892A (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542299B1 (en) * | 1991-11-15 | 1999-08-04 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Ester linkage containing polymers for use in pharmaceutical preparations |
US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
US6166024A (en) * | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
US20040018236A1 (en) * | 1995-05-08 | 2004-01-29 | Robert Gurny | Nanoparticles for oral administration of pharmaceutical agents of low solubility |
GB2300807B (en) * | 1995-05-15 | 1999-08-18 | Tillotts Pharma Ag | Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease |
AUPN327695A0 (en) * | 1995-05-30 | 1995-06-22 | Chemeq Pty. Limited | Chemotherapeutic compositions |
US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5908912A (en) * | 1996-09-06 | 1999-06-01 | Ppg Industries Ohio, Inc. | Electrodepositable coating composition containing bismuth and amino acid materials and electrodeposition method |
GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
DE19732903A1 (en) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet formulation for the treatment of the intestinal tract |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
US20090297597A1 (en) * | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
CN100444830C (en) * | 1998-11-02 | 2008-12-24 | 伊兰公司,Plc | Multiparticulate modified release composition |
BR9916972B1 (en) | 1999-01-29 | 2010-05-18 | improved delayed release pharmaceutical compositions as well as their production process. | |
ITMI991316A1 (en) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
KR101216270B1 (en) | 1999-10-29 | 2012-12-31 | 유로-셀티크 소시에떼 아노뉨 | Controlled release hydrocodone formulations |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
AU3984101A (en) | 2000-02-24 | 2001-09-03 | Advanced Pharma Inc | Antibiotic and antifungal compositions |
US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
IT1318376B1 (en) * | 2000-03-07 | 2003-08-25 | Pharmatec Internat S R L | ORAL SOLID FORMS WITH CONTROLLED RELEASE CONTAINING MESALAZINE AS AN ACTIVE PRINCIPLE. |
US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
US6824559B2 (en) * | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
FR2830446B1 (en) * | 2001-10-09 | 2004-02-06 | Univ Pasteur | PHARMACEUTICAL COMPOSITION FOR RELEASING AN ACTIVE SUBSTANCE AT THE COLON |
US8282955B2 (en) | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
JP2007523664A (en) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | Sachet for pharmaceutical composition |
JP2006528185A (en) * | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
EP1648407A4 (en) * | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
EP1648415A4 (en) * | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
JP2007502296A (en) * | 2003-08-11 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | Robust pellet |
AU2004264356B2 (en) * | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
EP1658034A4 (en) * | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
WO2005027877A1 (en) * | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
CA2550983C (en) * | 2003-12-24 | 2013-09-17 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
ES2407465T3 (en) | 2004-03-29 | 2013-06-12 | Galpharma Co., Ltd. | New modified galectin 9 protein and its use |
AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
CA2572292A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
DE14172398T1 (en) | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Controlled release of pharmaceutical compositions with fumaric acid ester |
US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
ITBO20050123A1 (en) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA |
US20060222700A1 (en) * | 2005-04-05 | 2006-10-05 | Groenewoud Pieter J | Tablet and capsule form of liquid active ingredient |
WO2006110807A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
WO2007037790A2 (en) * | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
US8865197B2 (en) * | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
ITMI20061692A1 (en) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA |
WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
AU2008310735B2 (en) * | 2007-10-12 | 2013-09-12 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal disorders independent of the intake of food |
US8772242B2 (en) * | 2009-10-26 | 2014-07-08 | Thomas Julius Borody | Therapy for enteric infections |
CA3107450A1 (en) | 2012-03-29 | 2013-10-03 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
KR102290178B1 (en) | 2013-03-13 | 2021-08-18 | 트리스 파마 인코포레이티드 | Benzonatate modified release solid tablets and capsules |
US9180104B2 (en) | 2013-03-13 | 2015-11-10 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
AU2014239683B2 (en) | 2013-03-15 | 2018-05-17 | Allergan Pharmaceuticals International Limited | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
US20200181649A1 (en) * | 2016-07-14 | 2020-06-11 | University Of Delaware | Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2021409B (en) * | 1977-05-25 | 1982-09-22 | Fisons Ltd | Pharmaceutical composition |
US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
FR2426477A1 (en) * | 1978-05-26 | 1979-12-21 | Monsanto Co | FIRE DELAY COMPOSITION INCLUDING IN PARTICULAR AMMONIUM SULPHATE AND A CARBOXYALKYL OR HYDROXYALKYL ETHER OF A POLYGALACTOMANNAN |
WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
SE8003805L (en) * | 1980-05-21 | 1981-11-22 | Haessle Ab | A PHARMACEUTICAL PREPARATION WITH IMPROVED EMISSION PROPERTY |
ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
DK150008C (en) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION |
IT1230576B (en) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON |
IL92343A0 (en) * | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
EP0386967B1 (en) * | 1989-03-10 | 1995-07-12 | Yamanouchi Pharmaceutical Co. Ltd. | A drug-release controlling coating material for long acting formulations |
JPH0334929A (en) * | 1989-06-29 | 1991-02-14 | Teikoku Seiyaku Kk | Oral administration composition for treating ulcerative colitis and crohn's disease |
US5260071A (en) * | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
JPH064531B2 (en) * | 1990-06-04 | 1994-01-19 | アイセロ化学株式会社 | Colon disintegrating hard capsule |
-
1991
- 1991-02-22 GE GEAP19912613A patent/GEP19971086B/en unknown
- 1991-02-22 GB GB9103795A patent/GB2253346A/en not_active Withdrawn
-
1992
- 1992-02-21 JP JP4505041A patent/JP2958116B2/en not_active Expired - Fee Related
- 1992-02-21 IN IN149DE1992 patent/IN179089B/en unknown
- 1992-02-21 ES ES92905384T patent/ES2079183T3/en not_active Expired - Lifetime
- 1992-02-21 WO PCT/GB1992/000318 patent/WO1992014452A1/en active IP Right Grant
- 1992-02-21 EP EP92905384A patent/EP0572486B1/en not_active Expired - Lifetime
- 1992-02-21 AT AT92905384T patent/ATE129893T1/en not_active IP Right Cessation
- 1992-02-21 DK DK92905384.1T patent/DK0572486T3/en active
- 1992-02-21 AU AU12795/92A patent/AU652032B2/en not_active Ceased
- 1992-02-21 CA CA002104686A patent/CA2104686C/en not_active Expired - Lifetime
- 1992-02-21 HU HU9302379A patent/HU219449B/en not_active IP Right Cessation
- 1992-02-21 YU YU17892A patent/YU17892A/en unknown
- 1992-02-21 US US08/107,744 patent/US5401512A/en not_active Expired - Lifetime
- 1992-02-21 IE IE920548A patent/IE74225B1/en not_active IP Right Cessation
- 1992-02-21 KR KR1019930702488A patent/KR100220322B1/en not_active IP Right Cessation
- 1992-02-21 CZ CS931626A patent/CZ281792B6/en not_active IP Right Cessation
- 1992-02-21 DE DE69205971T patent/DE69205971T2/en not_active Expired - Lifetime
- 1992-02-21 NZ NZ241687A patent/NZ241687A/en not_active IP Right Cessation
- 1992-02-21 IL IL10103692A patent/IL101036A/en not_active IP Right Cessation
-
1993
- 1993-08-20 NO NO932979A patent/NO307405B1/en not_active IP Right Cessation
- 1993-08-20 FI FI933680A patent/FI105255B/en not_active IP Right Cessation
-
1995
- 1995-12-19 GR GR950403588T patent/GR3018455T3/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2104686A1 (en) | Delayed Release Oral Dosage Forms for Treatment of Intestinal Disorders | |
US8101209B2 (en) | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | |
PT825858E (en) | DEPENDENT TIME-RELEASING CAPSULES CONTAINING POLYINSATURATED ACIDS OMEGA-3 FOR THE TREATMENT OF INFLAMMATORY DISEASE OF THE INTESTINE | |
KR970005177B1 (en) | Gastro-resistant pharmaceutical formulations for oral administration containing salts of bile acids | |
CA2065809A1 (en) | Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids | |
CA2065773A1 (en) | Gastroresistant pharmaceutical formulations for oral administration containing bile acids | |
NO830948L (en) | ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATIONS. | |
KR20020062970A (en) | Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor | |
HUP0000943A2 (en) | Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract | |
AU736357B2 (en) | Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient | |
CN109152772A (en) | The combination of oral medication of niacinamide | |
EP1108431B1 (en) | Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam | |
KR20020063871A (en) | Anti-inflammatory pharmaceutical formulations | |
CZ446299A3 (en) | Pharmaceutical preparation with controlled release and with ACE inhibitor as active substance | |
TH61079A (en) | Film-coated tablets for improved safety for the upper gastrointestinal tract. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKEC | Expiry (correction) |
Effective date: 20121202 |